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To the Editors
The prevalence of HIV-infected patients requiring chronic hemodialysis (HD) for end stage 
renal disease (ESRD) continues to increase.1 As such, determining the optimal dosing 
frequency of commonly used antiretrovirals is important to maintain viral suppression while 
avoiding toxicity. Tenofovir (TFV), administered as TFV disoproxil fumarate (TDF), and 
emtricitabine (FTC) are renally excreted and require dosing modification for patients with 
kidney disease. However, the dosing recommendations for these drugs in HD are based on 
single dose pharmacokinetic studies performed in HIV-uninfected persons with ESRD.2, 3 
Thus, it is important to determine the actual steady-state plasma and intracellular drug 
concentrations of these drugs for HIV-infected patients on hemodialysis. Understanding the 
pharmacokinetics of these drugs may also be useful if these agents are to be used by HIV-
negative patients on HD as pre-exposure prophylaxis to prevent HIV infection.
As such, we prospectively collected whole blood samples at three clinical sites from 11 HIV-
infected patients undergoing thrice weekly HD. All participants had been receiving either 
TDF 300 mg once weekly after HD (n=10) or FTC 200 mg twice weekly after HD (n=1) for 
at least four weeks to ensure that the measurements reflected steady state. Blood sampling 
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was performed immediately before HD on the day that the patient was scheduled to take the 
medication. Plasma TFV and FTC concentrations and peripheral blood mononuclear cell 
(PBMC) intracellular tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-
TP) concentrations were measured using high performance liquid chromatography methods 
with mass spectrometry detection as previously described.4 All participants provided 
written, informed consent. This study was approved by the respective Institutional Review 
Boards from the three enrolling sites.
These plasma and intracellular concentrations were then compared to historically reported 
controls with normal renal function receiving these drugs at steady state (Table 1).5-8 One 
study of TDF given as a single-dose to HIV-uninfected patients on HD was also included for 
comparison given that this study was used to guide formal dosing recommendations.2 We 
could not identify any published literature describing the pharmacokinetics of these drugs in 
HIV-infected patients requiring HD except for a single case report of TDF.9 We formally 
compared our results to these historical controls using geometric mean ratios (GMR), which 
were then analyzed using two-sided Student’s t-tests to determine if the GMR values were 
significantly different from unity. We also performed non-parametric tests of comparison, 
which provided similar results (data not shown). All analyses were performed using SAS 
v9.4 (SAS Institute, Cary, NC) with assumptions being verified at the time of analysis.
The median (range) age and duration of therapy with the medications under study were 56.0 
(24.6-65.8) years and 5.0 (3.1-10.5) years, respectively. The median (range) CD4 cell count 
and HIV-1 RNA level prior to drug initiation were, respectively, 391 (153-840)/μL, and 
24,826 (2,630-703,800) copies/mL. All had HIV-RNA levels <20 copies/mL at time of the 
study visit blood draw. All 11 participants were of self-reported black race, and 9 were men. 
None had active hepatitis B co-infection, hepatic cirrhosis, or serious illness within 30 days 
prior to the blood draw.
Due to sample collection and processing issues, plasma concentrations were available from 
five and PBMC intracellular concentrations from eight of the ten participants receiving TDF. 
The median (range) TFV plasma concentration was 660.0 (359.0 to 1019.6) ng/mL, with a 
mean (SD) value of 649.1 (266.3) ng/mL. The median (range) TFV-DP intracellular 
concentration was 317.4 (154.5 to 922.2) fmol/million cells, with a mean (SD) value of 
467.5 (333.9) fmol/million cells. The mean TFV plasma and intracellular GMRs were 
significantly greater than 1 when comparing to the historical groups with normal renal 
function but less than 1 when comparing to the uninfected historical HD group receiving a 
single dose of TDF (all P<0.05), albeit with substantial overlap in the ranges. Paired plasma 
and intracellular concentrations were available for three participants; the Spearman 
correlation between these two measures was 0.50 (P=0.67).
The one participant receiving FTC had a plasma concentration of 420 ng/mL, which is 
appreciably higher than the mean concentration of 57 ng/mL observed with daily dosing in 
historical controls with normal renal function. The FTC-TP concentration of 2260 fmol/
million cells was similar to the mean concentration of 4000 fmol/million cells observed in 
historical controls.
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To our knowledge, this is the first evaluation of tenofovir and emtricitabine steady-state 
concentrations in HIV-infected patients receiving HD. Even when TDF was given just once 
per week as recommended for those on HD, we found that TFV plasma and TFV-DP PBMC 
concentrations were much higher than those previously observed in persons with normal 
renal function. As higher circulating TFV concentrations may be associated with lower bone 
mineral density, the plasma TFV concentrations found in our study are potentially 
concerning. Whether switching TDF to tenofovir alafenamide, which is associated with 
much lower circulating TFV concentrations and improved bone mineral density,10 in 
patients on HD will result in improved bone mineral density is currently being assessed in an 
ongoing study (ClinicalTrials.gov NCT02600819). In contrast, the steady-state plasma TFV 
concentrations in the current study were significantly lower, albeit only modestly in absolute 
terms, compared to those measured in a single-dose PK study of HIV-uninfected persons 
receiving HD. This latter finding may not be clinically relevant in terms of virologic control, 
given the high intracellular TFV-DP concentrations found in our analysis.
Assuming that TFV tissue distribution is similar between HIV-infected and uninfected 
patients requiring HD, our data suggest that 300 mg of TDF given once weekly may be 
sufficient to prevent HIV acquisition, at least in uninfected men. In a modeling exercise from 
the iPrEX data, Anderson et al11 found that achieving intracellular TFV-DP concentrations 
>16 fmol/million cells was 90% effective in preventing HIV in men who have sex with men. 
Because TFV-DP is unstable over time in cryopreserved cells as used in the iPrEx analysis, 
it is not clear how these data compare to concentrations derived from freshly pelleted and 
frozen PBMC as done in our study. However, the lowest intracellular level in our TDF group 
was 154.5 fmol/million cells, which is appreciably higher than the 16 fmol/million cell 
threshold for protection identified in men in iPrEX. It remains to be determined if similar 
circulating levels are achievable in women requiring HD and would provide equivalent 
protection against HIV acquisition.
Our steady-state data for the one participant receiving FTC 200mg twice per week suggest 
that the plasma concentrations of this drug in HD are much higher than those found in 
patients with normal renal function receiving the same dosage daily. Given that FTC is well-
tolerated and without known major complications, our finding of a high plasma FTC 
concentration is likely not of major clinical concern. The intracellular concentration in our 
participant was similar to the historical control group with normal renal function. Although 
we were unable to perform statistical comparisons, to our knowledge these are the only 
available data evaluating steady state FTC levels in patients on HD.
We acknowledge that a full pharmacokinetic analysis delineating the entire concentration-
time curve of these drugs would provide more information regarding drug absorption and 
elimination. However, this would have entailed expensive and time-consuming procedures 
over a period of 4 to 7 days. We presumed that the concentrations obtained before dialysis 
on the day the study drug was administered would allow insight into the likely antiviral 
effectiveness of the drug over the entire dosing interval. Although the sample size of our 
study was small, this did not appear to limit the power to find differences in TFV 
concentrations between our population and historical control groups. Although 
unintentional, only men were included in these analyses, so we cannot extrapolate these 
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findings to women with HIV. Finally, we did not collect detailed information on residual 
renal function in our participants, and it is possible that plasma concentrations are lower in 
patients who have recently initiated HD and have greater residual renal function.
In summary, TDF given once weekly as recommended in HIV-infected patients on HD 
results in steady-state plasma and intracellular PBMC concentrations which are higher than 
those found in patients with normal renal function who are taking this drug daily. Additional 
study is required to determine if TDF could potentially be given even less frequently or at 
lower doses to patients on HD to achieve virologic suppression in those with HIV and to 
prevent HIV acquisition in those without HIV.
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